arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Nexalin Technology, Inc.

NXL
$0.36 ▲ +0.02 (+4.66%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
22 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nexalin Technology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.1M
Dividend Yield
Revenue Growth -63.5%
Op. Margin None
ROIC -58.0%
FCF / Share $-0.09
Trailing P/E
Price / Book 2.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.95K
↓ -63.5%
Net Income Profit after all expenses
$-2.10M
↓ -5.5%
Operating Margin Operating profit as % of sales
-53.8%
↑ +50.0%
FCF / Share Free cash flow per share
$-0.09
↑ +19.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Financial Health
5
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters